Vicore announced that it has selected diffuse systemic sclerosis ("dSSc") as the second rare disease indication for lead asset VP01 (C21), which is already in development for idiopathic pulmonary fibrosis ("IPF"). Phase IIa proof-of-concept trials for both indications are expected to start in H2/2019E, with data possible in mid-2021E. Based on the estimated prevalence and limited therapeutic options, our preliminary analysis suggests that dSSc could represent a sales opportunity for VP01 close t ....
25 Apr 2019
Scleroderma the second indication for VP01 (C21)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Scleroderma the second indication for VP01 (C21)
Vicore Pharma Holding AB (6Y4:FRA) | 0 0 0.0%
- Published:
25 Apr 2019 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
5
Vicore announced that it has selected diffuse systemic sclerosis ("dSSc") as the second rare disease indication for lead asset VP01 (C21), which is already in development for idiopathic pulmonary fibrosis ("IPF"). Phase IIa proof-of-concept trials for both indications are expected to start in H2/2019E, with data possible in mid-2021E. Based on the estimated prevalence and limited therapeutic options, our preliminary analysis suggests that dSSc could represent a sales opportunity for VP01 close t ....